Hip Dysplasia Compromises the Outcome of Femoroacetabular Impingement Surgery.


Journal

The Journal of arthroplasty
ISSN: 1532-8406
Titre abrégé: J Arthroplasty
Pays: United States
ID NLM: 8703515

Informations de publication

Date de publication:
05 2019
Historique:
received: 03 08 2018
revised: 08 01 2019
accepted: 11 01 2019
pubmed: 14 2 2019
medline: 29 2 2020
entrez: 14 2 2019
Statut: ppublish

Résumé

The optimal treatment for patients with symptomatic hip dysplasia presenting with labral tear is unknown. Although femoroacetabular osteoplasty (FAO) has excellent outcome for most femoroacetabular impingement patients, the presence of concomitant hip dysplasia has been implicated as an adverse prognostic factor. This study evaluated the outcome of FAO in a group of dysplastic hips and compared the outcome to a cohort of patients without dysplasia. Seventy-three patients (38 males, 35 females) with hip dysplasia who underwent FAO between 2007 and 2015 were identified. The minimum 2-year clinical, functional (modified Harris Hip Score and Short-Form 36 Health Survey), and radiological outcome was compared with 550 patients without dysplasia who underwent FAO by the same surgeon. The preoperative and postoperative alpha angle, Tonnis grade, joint space, and presence of chondral lesion were determined and compared. Conversion to total hip arthroplasty or revision FAO was considered as treatment failure. The mean age in the dysplasia cohort was 30.7 ± 11.8 years compared to 34.5 ± 11.2 in the nondysplastic group. The mean follow-up was 4.3 years for dysplasia cohort and 4.1 for the nondysplastic group. The mean modified Harris Hip Score and Short-Form 36 Health Survey6 was significantly lower in the dysplastic group at 75.1 and 74.3 compared to 83.4 and 85.6 for the comparison group. There was a higher percentage of failure at 28.8% among dysplasia patients compared to 2.5% in the nondysplastic group. Although labral repair and FAO may be an option for patients with hip dysplasia, the outcome in this population appears to be less optimal compared to femoroacetabular impingement patients with no evidence of dysplasia. Labral repair and osteoplasty should be limited to those with mild and borderline dysplasia.

Sections du résumé

BACKGROUND
The optimal treatment for patients with symptomatic hip dysplasia presenting with labral tear is unknown. Although femoroacetabular osteoplasty (FAO) has excellent outcome for most femoroacetabular impingement patients, the presence of concomitant hip dysplasia has been implicated as an adverse prognostic factor. This study evaluated the outcome of FAO in a group of dysplastic hips and compared the outcome to a cohort of patients without dysplasia.
METHODS
Seventy-three patients (38 males, 35 females) with hip dysplasia who underwent FAO between 2007 and 2015 were identified. The minimum 2-year clinical, functional (modified Harris Hip Score and Short-Form 36 Health Survey), and radiological outcome was compared with 550 patients without dysplasia who underwent FAO by the same surgeon. The preoperative and postoperative alpha angle, Tonnis grade, joint space, and presence of chondral lesion were determined and compared. Conversion to total hip arthroplasty or revision FAO was considered as treatment failure.
RESULTS
The mean age in the dysplasia cohort was 30.7 ± 11.8 years compared to 34.5 ± 11.2 in the nondysplastic group. The mean follow-up was 4.3 years for dysplasia cohort and 4.1 for the nondysplastic group. The mean modified Harris Hip Score and Short-Form 36 Health Survey6 was significantly lower in the dysplastic group at 75.1 and 74.3 compared to 83.4 and 85.6 for the comparison group. There was a higher percentage of failure at 28.8% among dysplasia patients compared to 2.5% in the nondysplastic group.
CONCLUSION
Although labral repair and FAO may be an option for patients with hip dysplasia, the outcome in this population appears to be less optimal compared to femoroacetabular impingement patients with no evidence of dysplasia. Labral repair and osteoplasty should be limited to those with mild and borderline dysplasia.

Identifiants

pubmed: 30755376
pii: S0883-5403(19)30055-5
doi: 10.1016/j.arth.2019.01.028
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

852-856

Informations de copyright

Copyright © 2019 Elsevier Inc. All rights reserved.

Auteurs

Hamed Vahedi (H)

Rothman Institute at Thomas Jefferson University, Philadelphia, PA.

Arash Aalirezaie (A)

Rothman Institute at Thomas Jefferson University, Philadelphia, PA.

Gabriella Rolo (G)

Rothman Institute at Thomas Jefferson University, Philadelphia, PA.

Javad Parvizi (J)

Rothman Institute at Thomas Jefferson University, Philadelphia, PA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH